Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 2009

View Archived Issues

Further results from ongoing phase I study of AC-220 show benefit in AML patients

AFP-464 synergistic with vorinostat in breast cancer cells

I-PRESERVE finds no benefit of irbesartan in heart failure with preserved ejection fraction

GlaxoSmithKline reports on discovery of EP1 receptor antagonist for inflammatory pain

Chalcone derivative blocks Abeta impairment of PKA/CREB signaling

Endo to acquire Indevus

EMEA accepts Cerepro Marketing Authorization Application for review

FDA lifts hold on Advaxis' phase II cervical intraepithelial neoplasia trial

Chimerix completes phase I and initiates phase II multidose trial for CMX-001

Genta summarizes phase II activity and receives orphan drug status for tesetaxel

Kythera reports positive phase II results for ATX-101 in submental fat reduction

YM's nimotuzumab to be evaluated in phase II and III trials for cancer

Phase III trial starts for GammaGard Liquid in primary immunodeficiency

CHMP recommends orphan drug status for ARG-201 in systemic sclerosis

Cubist submits two INDs targeting serious infections

Cytochroma commences phase I CTAP-201 injection in chronic kidney disease

Cylene initiates phase I trial with CK2 protein kinase inhibitor, CX-4945

ChemoCentryx divulges new chemokine CCR1 receptor antagonists for immune disorders

BioMarin and La Jolla enter worldwide agreement for Riquent

Novel DGAT-1 inhibitors discovered by Janssen researchers

GSK scientists describe new AMPA receptor agonists in recent patent

CureVac receives FDA IND approval for phase I/IIa mRNA vaccine trial

Novel ghrelin receptor ligands under development at GSK for treatment of obesity

Bayer Schering Pharma submits Visanne for registration in Europe for endometriosis

New antibacterial agents reported in recent Meiji Seika patent

Emergent BioSolutions ends activities to acquire Protein Sciences

UCB receives FDA complete response letter for Cimzia in RA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...